IVA

Inventiva SA

Add to Watchlist

Advanced Chart

4.020

+0.35(9.537%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.030

Open

3.700

VWAP

3.82

Vol

84.98K

Mkt Cap

559.39M

Low

3.680

Amount

325.00K

EV/EBITDA(TTM)

Total Shares

52.36M

323.18M

EV/OCF(TTM)

P/S(TTM)

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

Trade Smarter with Intellectia.AI

300K+ trust us for AI trading signals that capture market momentum early!

2 Analyst Rating

397.51% Upside

Wall Street analysts forecast IVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVA is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

397.51% Upside

Current: 4.020

Low

20.00

Averages

20.00

High

20.00

397.51% Upside

Current: 4.020

Low

20.00

Averages

20.00

High

20.00

Guggenheim

Etzer Darout

Strong Buy

Maintains

$12 → $9

2025-04-04

Reason

Guggenheim

Etzer Darout

Price Target

$12 → $9

2025-04-04

Maintains

Strong Buy

Reason

Guggenheim analyst Etzer Darout lowered the firm's price target on Inventiva to $9 from $12 and keeps a Buy rating on the shares. With the company now funded through topline due data in the second half of 2026, the firm updated its model based on recent MASH market trends and pricing, offset by greater marketing spend and a fully diluted share count based on the Structured Financing agreement, the analyst tells investors.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$13

2025-04-02

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$13

2025-04-02

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$13

2025-03-28

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$13

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$13

2025-01-30

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$13

2025-01-30

Reiterates

Strong Buy

Reason

Stifel

Annabel Samimy

Strong Buy

Maintains

$20 → $17

2024-11-22

Reason

Stifel

Annabel Samimy

Price Target

$20 → $17

2024-11-22

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Inventiva to $17 from $20 and keeps a Buy rating on the shares. The company removed its "biggest stock overhang" through an equity financing of up to EUR 348M in three tranches, the first of which was closed in October, the analyst tells investors. The firm, which notes cash is sufficient until Q2 of 2025 with access to future conditional tranches, reduced it price target to account for dilution.

UBS

Eliana Merle

Hold

Initiates

2024-11-12

Reason

UBS

Eliana Merle

Price Target

2024-11-12

Initiates

Hold

Reason

UBS initiated coverage of Inventiva with a Neutral rating and $3 price target. The firm thinks the company's pan-PPAR agonist lanifibranor, currently in Phase 3 for metabolic dysfunction-associated steatohepatitis with fibrosis stage 2 or 3, has shown "promising" Phase 2 data and as an oral could take a piece of the large MASH market. However, with Phase 3 data expected in the second half of 2026, UBS sees the next two years as an execution period for Inventiva.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Inventiva SA (IVA.O) is -3.34, compared to its 5-year average forward P/E of -5.21. For a more detailed relative valuation and DCF analysis to assess Inventiva SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.21

Current PE

-3.34

Overvalued PE

0.55

Undervalued PE

-10.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.10

Current EV/EBITDA

-5.44

Overvalued EV/EBITDA

0.73

Undervalued EV/EBITDA

-10.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

51.36

Current PS

28.89

Overvalued PS

97.27

Undervalued PS

5.44